Tetragenetics Revenue and Competitors
Estimated Revenue & Valuation
- Tetragenetics's estimated annual revenue is currently $3.7M per year.
- Tetragenetics's estimated revenue per employee is $155,000
Employee Data
- Tetragenetics has 24 Employees.
- Tetragenetics grew their employee count by 9% last year.
Tetragenetics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Project Manager | Reveal Email/Phone |
Tetragenetics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Tetragenetics?
Tetragenetics, Inc. is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. We accomplish this by harnessing the unique biology of Tetrahymena thermophila. Our technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express in conventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease. Development of recombinant subunit vaccines against human pathogens is now underway, and long-range efforts are being directed towards large-scale expression of genetically engineered monoclonal antibodies. Additionally, we are actively pursuing both an internal pipeline of hard-to-make proteins and monoclonal antibodies, as well as proteins in partnership with a number of biopharmaceutical companies.
keywords:N/A
N/A
Total Funding
24
Number of Employees
$3.7M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Tetragenetics News
TetraGenetics, a biopharmaceutical company developing novel therapeutics for autoimmune diseases, today announced it has received an investment in the company’s type 1 diabetes (T1D) program from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best e ...
Tetragenetics Inc., an Arlington, MA-based biotechnology company engaged in the expression of ion channel drug targets, received an approx. $1.54m grant from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH). The grant, which will be awarded o ...
Other Companies in Arlington
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.4M | 24 | 0% | N/A |
#2 | N/A | 24 | -20% | N/A |
#3 | $3.7M | 24 | 4% | N/A |
#4 | $2.4M | 24 | -17% | N/A |
#5 | $5.1M | 24 | -4% | N/A |